XFOR vs EVF Comparison

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.